|
|
Next Article 
REVIEW ARTICLE
The Therapeutic Potential of Ribozymes
Helen A. James and
Ian Gibson
From the School of Biological Sciences, University of East Anglia,
Norwich, Norfolk, UK.
Ribozymes are catalytic RNA molecules that recognize their target
RNA in a highly sequence-specific manner. They can therefore be used to
inhibit deleterious gene expression (by cleavage of the target mRNA) or
even repair mutant cellular RNAs. Targets such as the mRNAs of
oncogenes (resulting from base mutations or chromosome translocations,
eg, ras or bcr-abl) and viral genomes and transcripts
(human immunodeficiency virus-type 1 [HIV-1]) are ideal targets for
such sequence-specific agents. The aim of this review is therefore to
introduce the different classes of ribozymes, highlighting some of the
chemistry of the reactions they catalyze, to address the specific
inhibition of genes by ribozymes, the problems yet to be resolved, and
how new developments in the field give hope to the future for ribozymes
in the therapeutic field.
Blood, Vol. 91 No. 2 (January 15), 1998:
pp. 371-382
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Clote
RNALOSS: a web server for RNA locally optimal secondary structures
Nucleic Acids Res.,
July 1, 2005;
33(suppl_2):
W600 - W604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. V. Morris, R. A. Grahn, D. J. Looney, and N. C. Pedersen
Characterization of a mobilization-competent simian immunodeficiency virus (SIV) vector containing a ribozyme against SIV polymerase
J. Gen. Virol.,
June 1, 2004;
85(6):
1489 - 1496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Clark, W. Zacharias, L. Panaitescu, and W. G. McGregor
Ribozyme-mediated REV1 inhibition reduces the frequency of UV-induced mutations in the human HPRT gene
Nucleic Acids Res.,
September 1, 2003;
31(17):
4981 - 4988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. LAZAREV, I. PUSKARZ, and R. R. BREAKER
Substrate specificity and reaction kinetics of an X-motif ribozyme
RNA,
June 1, 2003;
9(6):
688 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kurzrock, H. M. Kantarjian, B. J. Druker, and M. Talpaz
Philadelphia Chromosome-Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics
Ann Intern Med,
May 20, 2003;
138(10):
819 - 830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen
Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential
Pharmacol. Rev.,
March 1, 2003;
55(1):
133 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Melo, T. P. Hughes, and J. F. Apperley
Chronic Myeloid Leukemia
Hematology,
January 1, 2003;
2003(1):
132 - 152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kurreck, B. Bieber, R. Jahnel, and V. A. Erdmann
Comparative Study of DNA Enzymes and Ribozymes against the Same Full-length Messenger RNA of the Vanilloid Receptor Subtype I
J. Biol. Chem.,
February 22, 2002;
277(9):
7099 - 7107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kruger, C. Beger, P. J. Welch, J. R. Barber, M. P. Manns, and F. Wong-Staal
Involvement of Proteasome alpha -Subunit PSMA7 in Hepatitis C Virus Internal Ribosome Entry Site-Mediated Translation
Mol. Cell. Biol.,
December 15, 2001;
21(24):
8357 - 8364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock
The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis
Cancer Res.,
March 1, 2001;
61(6):
2343 - 2355.
[Full Text]
|
|
|
|
|
|
|
M. W. N. Deininger, J. M. Goldman, and J. V. Melo
The molecular biology of chronic myeloid leukemia
Blood,
November 15, 2000;
96(10):
3343 - 3356.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bramlage, E. Luzi, and F. Eckstein
HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture
Nucleic Acids Res.,
November 1, 2000;
28(21):
4059 - 4067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cobaleda and I. Sanchez-Garcia
In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment
Blood,
February 1, 2000;
95(3):
731 - 737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, J. V. Melo, S. Tura, S. Giralt, and M. Talpaz
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies
Hematology,
January 1, 2000;
2000(1):
90 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G C M BLACK, M E BOULTON, P N BISHOP, and D McLEOD
Ophthalmology in the post-genomic era
Br. J. Ophthalmol.,
November 1, 1999;
83(11):
1215 - 1218.
[Full Text]
|
|
|
|
|
|
|
A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak
Nucleic Acid Therapeutics: State of the Art and Future Prospects
Blood,
August 1, 1998;
92(3):
712 - 736.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Patricia, R. Natarajan, A. N. Dooley, F. Hernandez, J.-L. Gu, J. A. Berliner, J. J. Rossi, J. L. Nadler, R. S. Meidell, and C. C. Hedrick
Adenoviral Delivery of a Leukocyte-Type 12 Lipoxygenase Ribozyme Inhibits Effects of Glucose and Platelet-Derived Growth Factor in Vascular Endothelial and Smooth Muscle Cells
Circ. Res.,
April 13, 2001;
88(7):
659 - 665.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
